Business Wire

Thales Unveils Data Risk Intelligence to Redefine Data Risk Visibility and Proactive Risk Mitigation

3.12.2024 10:00:00 EET | Business Wire | Press release

Share

Thales today announced the launch of Data Risk Intelligence, a groundbreaking Imperva Data Security Fabric (DSF) solution that proactively addresses the risks to data wherever it resides. This is the first solution uniting the risk and threat identification capabilities of the Imperva Data Security Fabric with the data protection capabilities of the Thales CipherTrust Data Security Platform, following Thales’s strategic acquisition of Imperva in December 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203485067/en/

In today’s modern digital landscape, organisations face challenges in managing security across an ever-growing attack surface while maintaining compliance with regulatory standards. With data and operations spread across cloud, on-premises and hybrid systems, security teams require constant, comprehensive visibility into where their data is, the types of data they have, and the potential risks to that data. In fact, according to the 2024 Thales Data Threat Report, 93% of enterprises reported an increase in threats compared to the previous year.

Empowering Security Teams and SOCs with Enhanced Visibility and Control

The combined intelligence and contextual insights from Data Risk Intelligence provide a unified visibility of risks to critical data with a unique view of the strength of encryption for data across an organisation’s entire data estate. With this enhanced visibility, Data Risk Intelligence empowers CIOs, CISOs, and data risk specialists to accurately identify the most critical data that are at risk by severity and likelihood, enabling them to effectively prioritise risk mitigation with clear recommendations for corrective action.

Data Risk Intelligence delivers a highly confident risk score and clear recommendations for corrective action that are based on a wide-ranging set of data risk indicators through advanced analytics, built upon user permissions, data source vulnerabilities, use of encryption following NIST standards, monitoring of suspicious activities, and other customisable inputs.

Todd Moore, Vice President, Data Security products at Thales: “The ability to view data risk in key dimensions across organisational risk, asset risk, and regulatory risk in one place is extremely impactful. Data Risk Intelligence is the first of many integrations between the Thales and Imperva platforms that empower our customers to protect their data and all the paths to it. Through our combined platforms, Thales has all the tools to help our customers understand their data security risks and provide a clear set of actions to mitigate these risks.”

“The risks to enterprise data are multi-dimensional and organisations are struggling to address the volume and breadth of these risks while still maintaining optimal business operations,” said Jennifer Glenn, Research Director, Data and Information Security at IDC Security and Trust Group. “Centralising data risk visibility and management offers valuable context about the data – and it’s vulnerabilities – enabling organisations to prioritise protection where it’s needed most.”

Key Benefits of Data Risk Intelligence:

  • Enhanced Risk Prioritisation: Combines risk-related intelligence from Data Security Fabric and CipherTrust Data Security Platform to deliver precise risk scores that drive confident decisions.
  • Comprehensive Visibility: Provides a unified view of data risks across the entire data estate, reducing complexity, delivering risk indicators, and recommending protective measures.
  • Customisable Risk Indicators: Allows organisations to tailor risk indicators to their specific environment, highlighting the most critical threats.
  • Encryption Integration: Leverages the encryption capabilities of the CipherTrust Data Security Platform to ensure data protection at all levels.
  • Advanced Analytics: Utilises posture-based and machine-learning behavioural risk indicators to identify and prioritise the highest-risk data.

DSF Data Risk Intelligence is available to customers who have a current Data Security Fabric Data 360 license.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cyber & Digital.
It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

View source version on businesswire.com: https://www.businesswire.com/news/home/20241203485067/en/

Contacts

PRESS
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye